Protalix BioTherapeutics (NYSE:PLX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Financial Contrast

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Protalix BioTherapeutics (NYSE:PLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and Protalix BioTherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	N/A
Protalix BioTherapeutics	$61.84 million	2.33	$8.31 million	$0.07	25.57

Protalix BioTherapeutics has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eloxx Pharmaceuticals and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Eloxx Pharmaceuticals and Protalix BioTherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0	0	0	0	0.00
Protalix BioTherapeutics	0	0	1	0	3.00

Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 570.39%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Eloxx Pharmaceuticals.

Summary

Protalix BioTherapeutics beats Eloxx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.